Literature DB >> 16335927

Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.

Tingyou Li1, Yoshio Fujita, Kimitaka Shiotani, Anna Miyazaki, Yuko Tsuda, Akihiro Ambo, Yusuke Sasaki, Yunden Jinsmaa, Ewa Marczak, Sharon D Bryant, Severo Salvadori, Lawrence H Lazarus, Yoshio Okada.   

Abstract

A series of dimeric Dmt-Tic (2',6'-dimethyl-L-tyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) analogues (8-14, 18-22) were covalently linked through diaminoalkane and symmetric or asymmetric 3,6-diaminoalkyl-2(1H)-pyrazinone moieties. All the compounds exhibited high affinity for both delta-opioid receptors [Ki(delta) = 0.06-1.53 nM] and mu-opioid receptors [Ki(mu) = 1.37-5.72 nM], resulting in moderate delta-receptor selectivity [Ki(mu)/Ki(delta) = 3-46]. Regardless of the type of linker between the Dmt-Tic pharmacophores, delta-opioid-mediated antagonism was extraordinarily high in all analogues (pA2 = 10.42-11.28), while in vitro agonism (MVD and GPI bioassays) was essentially absent (ca. 3 to >10 microM). While an unmodified N-terminus (9, 13, 18) revealed weak mu-opioid antagonism (pA2 = 6.78-6.99), N,N'-dimethylation (21, 22), which negatively impacts on mu-opioid-associated agonism (Balboni et al., Bioorg. Med. Chem. 2003, 11, 5435-5441), markedly enhanced mu-opioid antagonism (pA2 = 8.34 and 7.71 for 21 and 22, respectively) without affecting delta-opioid activity. These data are the first evidence that a single dimeric opioid ligand containing the Dmt-Tic pharmacophore exhibits highly potent delta- and mu-opioid antagonist activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335927     DOI: 10.1021/jm050377l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Authors:  Severo Salvadori; Claudio Trapella; Stella Fiorini; Lucia Negri; Roberta Lattanzi; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Gianfranco Balboni
Journal:  Bioorg Med Chem       Date:  2007-08-29       Impact factor: 3.641

2.  Novel multiple opioid ligands based on 4-aminobenzazepinone (Aba), azepinoindole (Aia) and tetrahydroisoquinoline (Tic) scaffolds.

Authors:  Steven Ballet; Ewa D Marczak; Debby Feytens; Severo Salvadori; Yusuke Sasaki; Andrew D Abell; Lawrence H Lazarus; Gianfranco Balboni; Dirk Tourwé
Journal:  Bioorg Med Chem Lett       Date:  2010-01-20       Impact factor: 2.823

3.  Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph.

Authors:  Yunden Jinsmaa; Ewa D Marczak; Gianfranco Balboni; Severo Salvadori; Lawrence H Lazarus
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

Review 4.  Developmental potential for endomorphin opioidmimetic drugs.

Authors:  Yoshio Okada; Yuko Tsuda; Severo Salvadori; Lawrence H Lazarus
Journal:  Int J Med Chem       Date:  2012-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.